Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


28. June 2021 | 11:15 CET

Pfizer, Sartorius, Defence Therapeutics: Health as an investment opportunity

  • Biotechnology
Photo credits: pixabay.com

Tremendous opportunities lie dormant in biotech companies. New therapeutic approaches are suitable for fighting civilization diseases such as cardiovascular problems, cancer and Alzheimer's. In recent years, there has been a whole series of scientific breakthroughs. Some studies have shown phenomenal possibilities. It is now up to innovative companies to turn laboratory findings into practical clinical results. For shareholders, the opportunities are plentiful.

time to read: 3 minutes by Nico Popp
ISIN: PFIZER INC. DL-_05 | US7170811035 , SARTORIUS AG O.N. | DE0007165607 , DEFENCE THERAPEUTICS INC | CA24463V1013


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Pfizer: Better to invest in big brother?

The fact that biotech companies are on the verge of finding a holy grail in many areas is something that even the big pharmaceutical multinationals, such as Pfizer, are aware of. Not for nothing did the US Company enter into a partnership with the German Company BioNTech early on when it came to mRNA vaccines. But Pfizer also shines in other areas: last year, sales of cancer drugs went up. Rare disease drugs also contributed to the strong results, generating 30% sales growth on their own. Although some former box-office hits, such as the drugs Lipitor and Norvasc, weakened in 2020, the overwhelming success of BioNTech and its vaccine should compensate for this in the current year.

Pfizer is making money with every dose. It is now clear that BioNTech is even a little better than AstraZeneca's product, which is also very good. It protects against the new virus variants and is therefore likely to remain on the shopping lists of countries and companies for some time to come. When it comes to renewing existing vaccine doses, BioNTech/Pfizer is also likely to have a strong position with customers. The share is extremely solid and should also have potential in the medium and long term.

Sartorius: The pandemic stock par excellence

One Company that quickly emerged as a winner in the pandemic is Sartorius. The specialist for disposables, laboratory instruments and consumables is the Corona stock par excellence. You do not need to look at the annual report to see that. The frequency with which we have all come into contact with Coronatests and other side effects of the pandemic in recent months alone proves the relevance of the Company from Göttingen.

In 2020, Sartorius' total sales revenue climbed a whopping 20%. Order intake even rose by more than 40%. Even though the pandemic currently seems to be under control, vaccination rates below 80% are likely to cause one or the other stutter in the economy and everyday life again in the fall - Sartorius products will continue to be needed. After the rally of the first wave, the share price has turned sideways a little. However, the fundamental direction is positive.

Defence Therapeutics: Vaccines against cancer become more likely

Unlike Pfizer and Sartorius, one Company that is not yet familiar to every market participant is Defence Therapeutics. The Company has developed its patented Accum™ technology designed to deliver active ingredients precisely to the source of infections or diseases. The technology can "piggyback" on specific agents using antibodies. These antibodies block a receptor at the affected site and guide the active ingredient into the cell. Accum™ specifically ensures that the antibody used is equipped with an amino acid chain that increases the cell nucleus concentration of the respective active ingredient, thus making it easier for it to enter the affected cells. As a second mainstay, Defence Therapeutics develops vaccines and a few weeks ago announced promising results of the vaccine AccuVAC-D001 in the treatment of mice suffering from cancer. The pre-clinical study showed that 70% of cases in mice with established solid tumors were cured.

Now, mice are not humans, and a pre-clinical study is not yet a breakthrough in the fight against cancer. But the results show that Defence Therapeutics is making promising progress around one of humanity's worst diseases. The Accum™ technology can be considered promising. Using partially aggressive drugs in a targeted manner can reduce side effects and possibly make certain forms of treatment worthwhile in the first place. The share price has already risen in recent weeks and is currently consolidating. Investors should take a closer look at Defence Therapeutics.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2021 | 12:17 CET | by Stefan Feulner

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

Read

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read